NASDAQ:SCNI Scinai Immunotherapeutics (SCNI) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free SCNI Stock Alerts $0.46 +0.01 (+2.23%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.45▼$0.4850-Day Range$0.45▼$0.5252-Week Range$0.43▼$2.27Volume4,332 shsAverage Volume24,608 shsMarket Capitalization$856,145.84P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get Scinai Immunotherapeutics alerts: Email Address Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Scinai Immunotherapeutics Stock (NASDAQ:SCNI)Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.Read More SCNI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SCNI Stock News HeadlinesApril 17, 2024 | morningstar.comScinai Immunotherapeutics Ltd ADR SCNIApril 10, 2024 | prnewswire.comScinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMGApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 9, 2024 | theglobeandmail.comScinai Immunotherapeutics (NASDAQ: SCNI), Scinai Bioservices Enter MSA with Ayana PharmaApril 8, 2024 | prnewswire.comScinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing ServicesMarch 12, 2024 | finance.yahoo.comScinai leadership to attend BIO-Europe Spring 2024February 29, 2024 | prnewswire.comScinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024February 13, 2024 | finance.yahoo.comScinai Welcomes Liat Halpert as Head of Business Development and SalesApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.February 3, 2024 | morningstar.comScinai Immunotherapeutics Ltd ADRJanuary 25, 2024 | finance.yahoo.comScinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Görlich on Louis-Jeantet PrizeJanuary 4, 2024 | finance.yahoo.comScinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross ProceedsJanuary 4, 2024 | finanznachrichten.deScinai Immunotherapeutics Ltd.: Scinai Immunotherapeutics CEO Issues Letter to ShareholdersJanuary 4, 2024 | finance.yahoo.comScinai Immunotherapeutics CEO Issues Letter to ShareholdersDecember 29, 2023 | msn.comScinai Immunotherapeutics to raise $1.7M through exercise of outstanding warrantsDecember 29, 2023 | finance.yahoo.comScinai Immunotherapeutics Announces Exercise of Outstanding Warrants for $1.69 Million in Gross ProceedsDecember 27, 2023 | finance.yahoo.comScinai (NASDAQ: SCNI) to Host Analyst and Investor Webinar on January 9December 23, 2023 | wsj.comScinai Immunotherapeutics Ltd. ADRDecember 21, 2023 | investing.comScinai Immunotherapeutics Ltd ADR (SCNI)December 12, 2023 | finance.yahoo.comScinai Announces Promising Results in a Psoriatic Human Skin ModelDecember 11, 2023 | finance.yahoo.comStudy published in Antiviral Research supports promise of Scinai Immunotherapeutics' coronavirus NanoAb as aerosolized prophylactic and therapeutic drugNovember 28, 2023 | finance.yahoo.comScinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders' Equity RuleNovember 20, 2023 | msn.comScinai Immunotherapeutics regains compliance with stockholders' equity ruleNovember 6, 2023 | finance.yahoo.comScinai Immunotherapeutics Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting its New CDMO Business UnitNovember 3, 2023 | finance.yahoo.comScinai Immunotherapeutics to Attend BIO-Europe Munich 2023November 3, 2023 | finance.yahoo.comScinai Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 3, 2023 | finance.yahoo.comEuropean Investment Bank (EIB) considering extending maturity of its financial facility contract with Scinai Immunotherapeutics in light of Scinai’s recent strategic pivotSee More Headlines Receive SCNI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Scinai Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/26/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:SCNI Previous SymbolNASDAQ:SCNI CUSIPN/A CIK1611747 Webwww.scinai.com Phone972-8-930-2529Fax972-8930-2531Employees33Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,800,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-49.31% Debt Debt-to-Equity RatioN/A Current Ratio4.36 Quick Ratio4.36 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.94) per share Price / Book-0.49Miscellaneous Outstanding Shares1,870,000Free Float730,000Market Cap$856,145.84 OptionableNot Optionable Beta2.50 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Amir Reichman M.B.A. (Age 48)M.Sc., CEO & Director Comp: $562.5kMr. Elad Mark B.Sc. (Age 42)Eng., M.B.A., Chief Operating Officer Comp: $277.02kDr. Tamar Ben-Yedidia Ph.D. (Age 60)Chief Science Officer Comp: $314.92kMr. Uri Ben-Or CPA (Age 54)CPA, M.B.A., MBA, Chief Financial Officer Comp: $582kMs. Dalit Weinstein FischerChief Technology OfficerMr. Joshua E. Phillipson B.Sc.M.B.A., Director of Communications & Investor RelationsLiat HalpertHead of Business Development & SalesMs. Moran Ahdout Fruchter L.L.B.Chief of StaffMerav KamenskyHead of Quality ControlMr. Maxim LeykinHead of EngineeringMore ExecutivesKey CompetitorsAcorda TherapeuticsNASDAQ:ACORTC BiopharmNASDAQ:TCBPAcorda TherapeuticsNASDAQ:ACORQWindtree TherapeuticsNASDAQ:WINTEloxx PharmaceuticalsNASDAQ:ELOXView All Competitors SCNI Stock Analysis - Frequently Asked Questions How have SCNI shares performed in 2024? Scinai Immunotherapeutics' stock was trading at $0.5954 on January 1st, 2024. Since then, SCNI shares have decreased by 23.1% and is now trading at $0.4578. View the best growth stocks for 2024 here. Are investors shorting Scinai Immunotherapeutics? Scinai Immunotherapeutics saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 22,500 shares, an increase of 309.1% from the March 31st total of 5,500 shares. Based on an average daily volume of 27,900 shares, the days-to-cover ratio is currently 0.8 days. View Scinai Immunotherapeutics' Short Interest. When is Scinai Immunotherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our SCNI earnings forecast. How do I buy shares of Scinai Immunotherapeutics? Shares of SCNI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SCNI) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scinai Immunotherapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
